newsfilter
← Latest News
GlobeNewswire·

ERYTECH Announces Completion of First Cohort in a Phase 1 Investigator Sponsored Trial of Eryaspase in First-Line Pancreatic Cancer

ERYTECH Announces Completion of First Cohort in a Phase 1 Investigator Sponsored Trial of Eryaspase in First-Line Pancreatic Cancer No dose-limiting toxicity reported in the first dose cohort Encouraging clinical activity observed in first patients